Avidity Biosciences Announces Pricing of Upsized Public Offering of Common Stock
Avidity Biosciences will use the funds, along with existing reserves, to advance late-stage clinical programmes, prepare for potential launches, expand commercial infrastructure, progress its AOC platform, and for general corporate needs.
Bookrunning Managers | 13/09/2025 | By Dineshwori
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy